Mount Yale Investment Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Mount Yale Investment Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$409K	Buy	+4,872	New	+$282K	0.01%	778

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mount Yale Investment Advisors's DNTH Position: Q1 2026 in Review

Mount Yale Investment Advisors opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 4,872 shares worth $409K. The stake represents 0.01% of the portfolio and ranks #778 among its holdings.

241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Mount Yale Investment Advisors held 4,872 shares of Dianthus Therapeutics worth $409K as of Q1 2026.
Dianthus Therapeutics was a new Mount Yale Investment Advisors position in Q1 2026.
Dianthus Therapeutics made up 0.01% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #778 holding.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.